In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly. Vertex Pharmaceuticals (VRTX) is experiencing positive momentum with an 11.4% stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results